Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | BL-M11D1 |
| Synonyms | |
| Therapy Description |
BL-M11D1 is an antibody-drug conjugate (ADC) comprising the CD33 antibody gemtuzumab linked to Ed-04, a topoisomerase I inhibitor, which potentially inhibits tumor growth (Cancer Res (2024) 84 (6_Supplement): 3139). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| BL-M11D1 | BL M11D1|BLM11D1 | CD33 Antibody 17 | BL-M11D1 is an antibody-drug conjugate (ADC) comprising the CD33 antibody gemtuzumab linked to Ed-04, a topoisomerase I inhibitor, which potentially inhibits tumor growth (Cancer Res (2024) 84 (6_Supplement): 3139). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT06714591 | Phase I | BL-M11D1 | Evaluate the Safety, Tolerability, Pharmacokinetic Profile, Efficacy of Bl-M11D1 | Recruiting | USA | 0 |